Skye Bio Positive Phase 1 Trial Results for the Treatment of Glaucoma

 • SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)

• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg)

https://www.princegeorgepost.com/newsfile/185167-skye-bioscience-announces-positive-phase-1-trial-results-for-sbi100-ophthalmic-emulsion-its-firstinclass-cb1-agonist-being-developed-for-the-treatment-of-glaucoma